Original articleHidradenitis suppurativa: A retrospective study of 846 Dutch patients to identify factors associated with disease severity
Section snippets
Methods
Between 2007 and 2013, we collected the data from all consecutive patients with HS referred to 3 Dutch clinics with a special interest in HS: the Department of Dermatology at Erasmus Medical Center, Rotterdam; the Department of Dermatology at Deventer Hospital, Deventer; and the Department of Plastic Surgery at Diaconessenhuis, Leiden. The respective diagnoses of HS in these hospitals were made by one of the authors or Duco G. van den Broecke, MD, (Department of Plastic Surgery,
Results
A total of 846 patients with HS were seen, 410 at Erasmus Medical Center, 404 at Deventer Hospital, and 32 at Diaconessenhuis, and were included and analyzed (Table I). The mean age was 38.0 ± 12.7 years, with mean disease duration of 13.8 ± 11.0 years. The majority of patients were female (72.6%). Approximately one-third had a normal weight (36.2%), one-third were overweight (31.5%), and another third were obese (32.3%). The overall body mass index (BMI) was 28.1 ± 6.1. A majority was current
Discussion
This analysis of 846 patients with HS in The Netherlands determined 5 severity risk factors: male sex, obesity, smoking pack-years, disease duration, and lesions in the axillary, perianal, and mammary regions.
Our finding of a higher risk of severe disease in males was previously suggested by Matusiak et al15 in 54 patients with HS, and more recently by Vazquez et al16 in 268 patients with HS. The outcome that obesity (measured as BMI) is a severity risk factor was in accordance with the results
References (16)
- et al.
Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity
J Am Acad Dermatol
(2009) - et al.
Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies
J Am Acad Dermatol
(2008) - et al.
Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions
J Am Acad Dermatol
(2010) - et al.
Hidradenitis suppurativa and associated factors: still unsolved problems
J Am Acad Dermatol
(2009) - et al.
Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota
J Invest Dermatol
(2013) Hidradenitis suppurativa
J Eur Acad Dermatol Venereol
(2009)- et al.
Psychophysical aspects of hidradenitis suppurativa
Acta Derm Venereol
(2010) - et al.
Psychosocial impact of hidradenitis suppurativa: a qualitative study
Acta Derm Venereol
(2011)
Cited by (178)
Taiwanese Dermatological Association (TDA) consensus recommendations for the definition, classification, diagnosis, and management of hidradenitis suppurativa
2024, Journal of the Formosan Medical AssociationEpidemiology of hidradenitis suppurativa
2023, Clinics in DermatologyFailure of dupilumab in a severe case of hidradenitis suppurativa
2023, Annales de Dermatologie et de VenereologieA Practical Guide for Primary Care Providers on Timely Diagnosis and Comprehensive Care Strategies for Hidradenitis Suppurativa
2023, American Journal of MedicineS2k guideline for the treatment of hidradenitis suppurativa/acne inversa (ICD-10 code L73.2)
2024, Aktuelle DermatologieDrivers of disease severity and burden of hidradenitis suppurativa: a cross-sectional analysis on 553 German patients
2024, International Journal of Dermatology
Funding sources: None.
Disclosure: Dr Prens received grants from AbbVie (Grant number: PSA 45232, February 6, 2011), and is on the advisory board of AbbVie. Dr Schrader, Deckers, van der Zee, and Boer have no conflicts of interest to declare.